ES2720954T3 - Formulaciones estabilizadas de estatina - Google Patents

Formulaciones estabilizadas de estatina Download PDF

Info

Publication number
ES2720954T3
ES2720954T3 ES11769321T ES11769321T ES2720954T3 ES 2720954 T3 ES2720954 T3 ES 2720954T3 ES 11769321 T ES11769321 T ES 11769321T ES 11769321 T ES11769321 T ES 11769321T ES 2720954 T3 ES2720954 T3 ES 2720954T3
Authority
ES
Spain
Prior art keywords
atorvastatin
statin
buffer
pharmaceutically acceptable
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11769321T
Other languages
English (en)
Inventor
Leo Pavliv
Andrew Vila
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cumberland Pharmaceuticals Inc
Original Assignee
Cumberland Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cumberland Pharmaceuticals Inc filed Critical Cumberland Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2720954T3 publication Critical patent/ES2720954T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulacion farmaceutica liquida que es una solucion acuosa que comprende una cantidad eficaz de atorvastatina o una sal farmaceuticamente aceptable de la misma, complejada con una cantidad eficaz de un agente complejante farmaceuticamente aceptable, que es hidroxil-propil-ß-ciclodextrina, para hacer que la atorvastatina sea soluble en agua, un agente de ajuste del pH seleccionado entre el grupo que consiste en un agente alcalinizante, un tampon, y una combinacion de un agente alcalinizante y un tampon, y un antioxidante opcional en una solucion acuosa que tiene un pH de 7 a 9 para proporcionar una concentracion de atorvastatina solubilizada de al menos 3,32 mg/ml.
ES11769321T 2010-04-16 2011-04-06 Formulaciones estabilizadas de estatina Active ES2720954T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/762,025 US8372877B2 (en) 2010-04-16 2010-04-16 Stabilized statin formulations
PCT/US2011/031388 WO2011130079A1 (en) 2010-04-16 2011-04-06 Stabilized statin formulations

Publications (1)

Publication Number Publication Date
ES2720954T3 true ES2720954T3 (es) 2019-07-25

Family

ID=44788660

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11769321T Active ES2720954T3 (es) 2010-04-16 2011-04-06 Formulaciones estabilizadas de estatina

Country Status (10)

Country Link
US (8) US8372877B2 (es)
EP (2) EP2557919B1 (es)
JP (2) JP5938394B2 (es)
KR (1) KR101462326B1 (es)
CN (1) CN102892287B (es)
AU (1) AU2011240925B2 (es)
BR (1) BR112012026465A2 (es)
CA (1) CA2799550C (es)
ES (1) ES2720954T3 (es)
WO (1) WO2011130079A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
WO2012054321A2 (en) 2010-10-19 2012-04-26 University Of Miami Assays, methods and kits for predicting renal disease and personalized treatment strategies
WO2013034436A1 (de) * 2011-09-08 2013-03-14 Hexal Ag Pharmazeutische zusammensetzung zur oralen darreichung mit einem statin
MX371073B (es) * 2012-04-13 2020-01-15 L&F Res Llc Método para utilizar ciclodextrina.
JP6053945B2 (ja) * 2012-11-23 2016-12-27 ペキン ユニバーシティ サード ホスピタルＰｅｋｉｎｇ Ｕｎｉｖｅｒｓｉｔｙ Ｔｈｉｒｄ Ｈｏｓｐｉｔａｌ 肥満症、糖尿病、高血圧症及び高脂血症を治療するための局所薬としてのスタチン化合物の使用
US9974767B2 (en) 2014-07-14 2018-05-22 University Of Washington Statins in the treatment of muscular dystrophies and myopathies
KR101686881B1 (ko) * 2014-07-25 2016-12-20 연세대학교 산학협력단 스타틴을 포함하는 갑상선 안병증의 예방 또는 치료용 약제학적 조성물
JP6355688B2 (ja) * 2016-09-01 2018-07-11 ペキン ユニバーシティ サード ホスピタルＰｅｋｉｎｇ Ｕｎｉｖｅｒｓｉｔｙ Ｔｈｉｒｄ Ｈｏｓｐｉｔａｌ 虚血性疾患の治療におけるスタチンの使用
KR102099627B1 (ko) 2018-04-13 2020-04-10 (주)바이오리치 냉이 추출물 및 신이 추출물을 유효성분으로 포함하는 지질 대사 개선용 조성물
CN110237055B (zh) * 2019-07-15 2021-09-07 江苏中兴药业有限公司 一种水飞蓟宾与辛伐他汀的药物组合物及其制备方法与应用
JP2024509376A (ja) * 2021-02-18 2024-03-01 ベレン セラピューティクス ピー．ビー．シー． 家族性ヘテロ接合型及びホモ接合型高コレステロール血症のシクロデキストリンによる治療方法
GB2624171A (en) 2022-11-08 2024-05-15 Novumgen Ltd An orally disintegrating tablet containing atorvastatin and process of preparing the same
WO2025221463A1 (en) * 2024-04-19 2025-10-23 Prevep, Inc. Pharmaceutical compositions comprising atorvastatin, or a salt thereof, and a liquid carrier

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4246227A (en) 1979-02-26 1981-01-20 Trayco, Inc. Method of making a unitary bowl, waterway, and trap for a toilet
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
HU204253B (en) 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4588715A (en) 1984-06-04 1986-05-13 Sandoz, Inc. Heptenoic acid derivatives
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4804679A (en) 1984-07-24 1989-02-14 Sandoz Pharm. Corp. Erythro-(E)-7-(3'-C1-3alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl)-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US5001255A (en) 1984-12-04 1991-03-19 Sandoz Pharm. Corp. Idene analogs of mevalonolactone and derivatives thereof
US4755606A (en) 1985-05-22 1988-07-05 Sandoz Pharm. Corp. Imidazolyl-3,5-di-(diphenyl-butylsilyloxy) carboxylic acid ester intermediates
US4808607A (en) 1985-05-22 1989-02-28 Sandoz Pharm. Corp. Imidazole analogs of mevalonolactone and derivatives thereof for use in inhibiting cholesterol biosynthesis and lowering blood cholesterol level
US4851427A (en) 1985-10-25 1989-07-25 Sandoz Pharm. Corp. Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use
US4927851A (en) 1986-01-07 1990-05-22 Sandoz Pharm. Corp. Analogs of mevalonolactone and derivatives thereof
US4829081A (en) 1986-01-07 1989-05-09 Sandoz Pharm. Corp. Analogs of mevalonolactone and derivatives thereof
US4939159A (en) 1986-09-10 1990-07-03 Sandoz Pharm. Corp. Azaindole derivatives useful as cholesterol biosynthesis inhibitors
US4751235A (en) 1986-12-23 1988-06-14 Sandoz Pharm. Corp. Anti-atherosclerotic indolizine derivatives
DE3817808A1 (de) 1987-07-21 1989-02-02 Bayer Ag Verfahren zur herstellung von 2-substituierten pyrrolen
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
EP0308736A3 (en) 1987-09-12 1990-02-14 Nissan Chemical Industries Ltd. Pyrimidine type mevalonolactones
US4868185A (en) 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
DE3800785A1 (de) 1988-01-09 1989-07-20 Hoechst Ag Substituierte 7-(pyridazin-5-yl)-3,5-dihydroxyheptan(en)- saeuren, ihre entsprechenden (delta)-lactone bzw. derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
US4822799A (en) 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
NO890521L (no) 1988-02-25 1989-08-28 Bayer Ag Substituerte pyrimidiner.
US4876280A (en) 1988-03-10 1989-10-24 Sandoz Pharm. Corp. Arylcyclohexane and arylcyclohexene analogs of mevalonolactone derivatives and their use
NO893909L (no) 1988-10-03 1990-04-04 Glaxo Group Ltd Fremgangsmaate for fremstilling av terapeutisk aktive imidazol-derivater.
AU3214689A (en) 1988-10-06 1990-05-01 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
CZ288545B6 (cs) 1995-12-22 2001-07-11 Kowa Company, Ltd. Stabilizovaná farmaceutická kompozice na bázi kyseliny (E)-3,5-dihydroxy-7-[4´-4´´-fluorfenyl-2´-cyklopropylchinolin-3´-yl]-6-heptenové
US6699849B1 (en) * 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
KR100660665B1 (ko) 1999-03-05 2006-12-21 닛폰세이시가부시키가이샤 감열기록체
AU2002241823A1 (en) 2001-01-11 2002-07-24 Eastman Chemical Company Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
US6566347B1 (en) 2001-08-22 2003-05-20 Duquesne University Of The Holy Ghost Controlled release pharmaceutical
WO2003068191A1 (en) * 2002-02-14 2003-08-21 Ranbaxy Laboratories Limited Formulations of atorvastatin stabilized with alkali metal additions
CN1232539C (zh) * 2002-05-10 2005-12-21 刘云清 有机药物与倍他环糊精衍生物的配合物及其制备方法
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7842716B2 (en) * 2004-03-29 2010-11-30 HeartDrug Research, LLC Treating vascular events with statins by inhibiting PAR-1 and PAR-4
WO2006046109A1 (en) * 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
ES2277743B2 (es) * 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
US20090247603A1 (en) * 2005-12-23 2009-10-01 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP2061583B1 (en) 2006-09-14 2019-04-10 Yissum Research Development Company, of The Hebrew University of Jerusalem Organic nanoparticles obtained from microemulsions by solvent evaporation
ES2310122B1 (es) * 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
CN101658677A (zh) * 2009-09-09 2010-03-03 重庆大学 洛伐他汀-磺丁基醚-β-环糊精包合物、制剂及制备方法
US8372877B2 (en) 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations

Also Published As

Publication number Publication date
US20210106561A1 (en) 2021-04-15
JP6178444B2 (ja) 2017-08-09
EP2557919A4 (en) 2013-12-25
JP5938394B2 (ja) 2016-06-22
AU2011240925B2 (en) 2015-01-15
US20150065553A1 (en) 2015-03-05
CN102892287A (zh) 2013-01-23
US20200316022A1 (en) 2020-10-08
EP2557919A1 (en) 2013-02-20
CA2799550A1 (en) 2011-10-20
CN102892287B (zh) 2014-11-05
HK1180541A1 (en) 2013-10-25
AU2011240925A1 (en) 2012-11-15
CA2799550C (en) 2015-03-17
EP3524053A1 (en) 2019-08-14
US20180036282A1 (en) 2018-02-08
US8372877B2 (en) 2013-02-12
US20110257240A1 (en) 2011-10-20
EP2557919B1 (en) 2019-01-30
US8933115B2 (en) 2015-01-13
US9820966B2 (en) 2017-11-21
WO2011130079A1 (en) 2011-10-20
JP2016166179A (ja) 2016-09-15
US20130137745A1 (en) 2013-05-30
JP2013525301A (ja) 2013-06-20
KR20130020788A (ko) 2013-02-28
BR112012026465A2 (pt) 2017-07-11
KR101462326B1 (ko) 2014-11-14
US20180344693A1 (en) 2018-12-06
US20160128977A9 (en) 2016-05-12
US20190117621A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
ES2720954T3 (es) Formulaciones estabilizadas de estatina
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
MX352949B (es) Composicion farmaceutica.
MX362382B (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
ES2531083T3 (es) Formulaciones estables de polipéptidos y usos de las mismas
DOP2012000261A (es) Formulaciones de insulina de accion prolongada
CL2017000829A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino.
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
AR081364A1 (es) Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
PE20230169A1 (es) Suministro al sistema nervioso central de agentes terapeuticos
CL2011002634A1 (es) Disolucion acuosa sin alcohol etilico que comprende propanolol o una sal farmaceuticamente aceptable del mismo, un edulcorante tipo no azucarado y menos del 0,01 % (p/v) de un agente conservante; procedimiento de preparacion; uso de la disolucion en el tratamiento de hemangiomas.
NZ591810A (en) Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
CU23367A3 (es) Formulación de moxifloxacino con sal común
CL2013003163A1 (es) Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.
MX373040B (es) Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservador.
AR081520A1 (es) Composicion farmaceutica que comprende una dispersion solida de tacrolimus en un vehiculo
AR053737A1 (es) Formulacion pediatrica de topiramato
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.
AR096773A1 (es) Formulación líquida estable
AR034370A1 (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral
UY38055A (es) Composiciones oftálmicas de compuestos de bencimidazol para uso unico diario
MX2014009660A (es) Formulacion de anticuerpo anti-selectina p.
EA201270745A1 (ru) Улучшенный стабильный водный состав (e)-4-карбоксистирил-4-хлорбензилсульфона
PE20151543A1 (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso